Results 191 to 200 of about 287,181 (244)

Estimating the incidence of heart failure: Insights from an illness-death model using statutory health insurance data from 70 million people in Germany. [PDF]

PLoS One
Wagner M, Rottländer D, Voß S, Brinks R.   +3 more
europepmc   +1 more source

Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Children with primary immunodeficiency (PID) and secondary antibody deficiency (SAD) often require immunoglobulin replacement therapy due to low plasma immunoglobulin G (IgG) levels and recurrent infections. Existing pharmacokinetic models for immunoglobulin in PID patients predominantly focus on adults, with limited attention to ...
Iek Leng Cheng, Zhong Hui Huang, Austen Worth, Claire Booth, Joseph F. Standing   +4 more
wiley   +1 more source

Population pharmacokinetics of rivaroxaban after transjugular intrahepatic portosystemic shunt. [PDF]

Eur J Clin Pharmacol
Jia M, Chai Y, Gao Y, Jing C, Zhu K, Zhu T, Wang L, Sun A, Yang J, Zhu Y, Feng Y, Cao Y, Li J.   +12 more
europepmc   +1 more source

Model‐informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Population pharmacokinetic (popPK) and pharmacokinetic‐pharmacodynamic (PK/PD) models were developed to support clinical development of nemolizumab, a humanized monoclonal antibody targeting the IL‐31 receptor α, in adolescents and adults with moderate‐to‐severe atopic dermatitis (AD).
Floris Fauchet, Anna Largajolli, Petra M. Jauslin, Emilie Schindler, Mourad Hamimed, Wannee Kantasiripitak, Antonio Gonçalves, Eline Van Maanen, Khaled Benkali, Tomohisa Saito, Jonathan I. Silverberg, Andreas Wollenberg, Michael Graeber, Liliana Ulianov, Christophe Piketty, Luca Loprete, Vincent Duval, Nathalie Wagner   +17 more
wiley   +1 more source

Multicomponent stress-strength reliability analysis using the inverted exponentiated rayleigh distribution under block adaptive type-II progressive hybrid censoring and k-records. [PDF]

Sci Rep
Newer HA.
europepmc   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

Correction: Genome-wide identification and expression profiling of the MADS-box gene family in Lavandula angustifolia. [PDF]

BMC Genomics
Li Y, Xiang J, Wang X, Ren J, Liu D, Zhang D, Guo D, Ma B.   +7 more
europepmc   +1 more source

Completion vs. early discontinuation of chemotherapy and the impact on 5‐year all‐cause mortality in women treated for early‐stage breast cancer from 2015 to 2020: A cohort study using a target trial emulation approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Chemotherapy is given for early‐stage breast cancer; however, some patients discontinue before completing all planned cycles. This study investigated the impact of early chemotherapy discontinuation on treatment outcomes. Methods This retrospective cohort study used a target trial emulation framework to conduct a causal analysis of the all‐
Luke Steventon, Chengsheng Ju, Kenneth K. C. Man, Rebecca Roylance, Diego Ottaviani, Chiara Creed, Michal Sladkowski, Alec Wisner, Li Wei, Pinkie Chambers   +9 more
wiley   +1 more source

A parsimonious nomogram for individualized prediction of 1-year functional outcome after STN-DBS in Parkinson's disease: a single-center retrospective study. [PDF]

Front Neurol
Zhang Y, Zhu Q, Fang B, Geng F.
europepmc   +1 more source

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, EarlyView.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source